Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements.
about
Bacterial outer membrane vesicles and vaccine applicationsLiposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and ImmunostimulatorsVaccines against tuberculosis: where are we and where do we need to go?Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protectionCAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferretsA liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cellsLocal Th17/IgA immunity correlate with protection against intranasal infection with Streptococcus pyogenes.Protection against Chlamydia promoted by a subunit vaccine (CTH1) compared with a primary intranasal infection in a mouse genital challenge model.Lactobacillus plantarum producing a Chlamydia trachomatis antigen induces a specific IgA response after mucosal booster immunization.Simultaneous Subcutaneous and Intranasal Administration of a CAF01-Adjuvanted Chlamydia Vaccine Elicits Elevated IgA and Protective Th1/Th17 Responses in the Genital Tract.Syringe free vaccination with CAF01 Adjuvated Ag85B-ESAT-6 in Bioneedles provides strong and prolonged protection against tuberculosis.Th17 cytokines and vaccine-induced immunity.Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01.Alternatives to mineral oil adjuvants in vaccines against Aeromonas salmonicida subsp. salmonicida in rainbow trout offer reductions in adverse effectsCutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate.CD4+ T cells and antibody are required for optimal major outer membrane protein vaccine-induced immunity to Chlamydia muridarum genital infection.Small cationic DDA:TDB liposomes as protein vaccine adjuvants obviate the need for TLR agonists in inducing cellular and humoral responsesIncreased immunogenicity and protective efficacy of influenza M2e fused to a tetramerizing proteinThe Mincle-activating adjuvant TDB induces MyD88-dependent Th1 and Th17 responses through IL-1R signalingVaccination against Chlamydia genital infection utilizing the murine C. muridarum model.Protective effect of a lipid-based preparation from Mycobacterium smegmatis in a murine model of progressive pulmonary tuberculosis.Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation.Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model.ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccination.The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirusProtein energy malnutrition during vaccination has limited influence on vaccine efficacy but abolishes immunity if administered during Mycobacterium tuberculosis infectionChlamydia muridarum T cell antigens and adjuvants that induce protective immunity in miceCharacterization of the Antigen-Specific CD4(+) T Cell Response Induced by Prime-Boost Strategies with CAF01 and CpG Adjuvants Administered by the Intranasal and Subcutaneous RoutesPowerful Complex Immunoadjuvant Based on Synergistic Effect of Combined TLR4 and NOD2 Activation Significantly Enhances Magnitude of Humoral and Cellular Adaptive Immune Responses.Vaccine-induced th17 cells are maintained long-term postvaccination as a distinct and phenotypically stable memory subset.Intramuscular Priming and Intranasal Boosting Induce Strong Genital Immunity Through Secretory IgA in Minipigs Infected with Chlamydia trachomatis.Particle-based platforms for malaria vaccines.Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogensA multi-subunit Chlamydia vaccine inducing neutralizing antibodies and strong IFN-γ⁺ CMI responses protects against a genital infection in minipigsCell-mediated and humoral immune responses after immunization of calves with a recombinant multiantigenic Mycobacterium avium subsp. paratuberculosis subunit vaccine at different ages.Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolateGlycomaterials for probing host-pathogen interactions and the immune response.Modulation of Primary Immune Response by Different Vaccine Adjuvants.Trehalose diester glycolipids are superior to the monoesters in binding to Mincle, activation of macrophages in vitro and adjuvant activity in vivoUpdate in tuberculosis 2008.
P2860
Q24568229-C5F5449C-55FA-4BA9-A488-D1EFDAC28087Q26765446-24BC6197-E3E5-459D-B11C-AC8D078BDDACQ26992233-C6A47BF7-4DD5-4CCC-BA62-AFFBFCDE4B9FQ27305883-477D68D2-D885-40C7-8E5F-AA0307CFD759Q28741710-03F9B5DF-54BD-4DF6-BF13-B28CCFE06305Q33459148-67FA5DE9-B4B7-43AE-AA6E-8677A53B59EAQ33570612-A3DCBFEA-6EC7-497D-A199-8B8D8E46218EQ33588632-072CB683-7484-45BE-80C3-C04C529D8554Q33632705-0ACDD43A-CB5E-427E-B8C1-CF11DFFCF6ACQ33694896-F7BCD78F-014A-4CA7-AB10-976EBCE82A5BQ33760570-70BE7CDE-C0C3-4529-A3EB-F99DFEB9F515Q33792227-0D6E89E8-9D13-4A91-8C9F-0AEAC4000128Q33793770-450F20F4-A6BE-4039-A828-913FD98A781AQ33918586-2E54B93A-7136-4E68-B5ED-B7B09496475AQ34099417-3324D084-03FD-4944-9307-AB4E4FEA2E73Q34177368-E154F94F-1BFD-4859-951C-A407BC8D32E5Q34217826-8566E50B-87CA-4F24-BDB7-97CC7CBEF1F4Q34437654-77D002F0-A2A3-4729-A5EF-3F65044CD809Q34545176-3A41AECE-0298-4235-815B-D1DFEAF4C66CQ34739969-289D8DA5-3643-4329-8735-40EE6BFE3B06Q34762605-4724EDAA-0AD6-4EBD-B23C-CD4DD760E0E9Q34920323-C4E968C0-DBA1-4BA3-B71F-2640C9EE8F95Q34984724-F201106F-C5C8-466F-A707-6C42B5B5F5F8Q35069386-B1289B11-8091-4F0C-9C92-2CABED2A399AQ35177864-9A1681CC-C6F0-46F5-83AD-AA9717A0F86EQ35439452-8C49D8E2-690D-42AA-80DB-BF5AEA97C730Q35867557-1C7A3AB1-554E-48A1-9DDD-C351F918F08CQ36002296-0D1C7A0D-6BF9-4A0A-B53A-19DA46A80301Q36020045-2EFB0421-00A2-4664-985E-CFE237C34158Q36277359-78E32573-53FC-49B9-AB73-EF8DC05034A7Q36373913-26377D7E-6D91-4EA4-9A2B-13A3D80A76D5Q36396040-2F9B8A19-30F0-425D-952E-697D59D1489EQ36500269-0E10A4AE-903B-4779-A2AD-FC33C1487C4FQ36564785-11926708-A6B3-4A15-B8AD-057C48C1E585Q36757836-8267393F-06AE-4E1C-9A49-8044B0FF016AQ37060319-2FF956D1-C482-4C81-9ABC-87C5473E9C0FQ37107154-9B81FBEC-A22A-4ABB-A84E-FDCC330BF7A5Q37342800-D64C289C-2F9F-438A-8024-947AF12C91BAQ37398283-6B633EEC-2661-4185-A07B-529585C6FB90Q37398528-D3F4E2E3-4C90-4453-B7EA-3F3C0978D8D9
P2860
Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements.
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Cationic liposomes formulated ...... nt immunological requirements.
@ast
Cationic liposomes formulated ...... nt immunological requirements.
@en
type
label
Cationic liposomes formulated ...... nt immunological requirements.
@ast
Cationic liposomes formulated ...... nt immunological requirements.
@en
prefLabel
Cationic liposomes formulated ...... nt immunological requirements.
@ast
Cationic liposomes formulated ...... nt immunological requirements.
@en
P2093
P2860
P50
P1433
P1476
Cationic liposomes formulated ...... nt immunological requirements.
@en
P2093
Brian S Vandahl
Carsten Kirschning
Claus Aagaard
Else Marie Agger
Ida Rosenkrands
Jon Hansen
Karima Brahimi
Kerstin Werninghaus
Michael Theisen
P2860
P356
10.1371/JOURNAL.PONE.0003116
P407
P577
2008-09-08T00:00:00Z